Medical Oncology

GIST

Questions discussed in this category

Would you recommend imatinib 400 mg BID or stay with the usual dose of 400 mg/day for adjuvant therapy for a patient with intermediate-high risk exon 9 mutated GIST?

1 Answer available

How do you treat metastatic, wild-type GIST?

1 Answer available

How do you approach adjuvant therapy for a resected gastric GIST when the risk for recurrence is discordant between various prediction tools?

For example, gastric GIST, < 5 mitoses/hpf and size > 5 cm but < 10 cm is intermediate by NIH criteria but low by NCCN/CAP criteria. Th...

1 Answer available

Outside of a clinical trial, how do you approach upfront therapy for a PDGFRA D842V-mutant GIST?

Would your recommendations change in the neoadjuvant versus adjuvant or metastatic setting?

2 Answers available

How do you approach non-surgical patients with GIST who are intolerant to imatinib 400 mg daily and unlikely to tolerate other TKIs?

Do you reduce the dose to <400 mg daily or employ dosing schedules?

2 Answers available

How do you choose your next line of therapy for stage 4 GIST after progression on imatinib?

How do you choose between local therapy (surgical debulking or ablation) v. 2nd line systemic therapy? Would you consider immunotherapy?

2 Answers available

Papers discussed in this category

JAMA Oncol,

Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.

The Lancet. Oncology, 2009-11

Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis.

Ann. Surg. Oncol., 2015 Feb 05

Validation of the MSKCC Gastrointestinal Stromal Tumor Nomogram and Comparison with Other Prognostication Systems: Single-Institution Experience with 289 Patients.

Related Topics in Medical Oncology